drugset / Trial / NCT01222468
Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
Phase 2
Completed
12 enrolled
University of Manitoba
Canadian Paraplegic Association · collabHealth Sciences Centre Foundation, Manitoba · collabThe Manitoba Spinal Cord Injury Research Fund · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study is being conducted to study the effect of nabilone (a synthetic cannabinoid)on spasticity in spinal cord injured persons.The study will be a phase 2, randomized, placebo-controlled crossover study. Each eligible subject will participate for 26 weeks.Subjects will be randomized to receive either nabilone or placebo during phase 1 of the study. Study drug will be titrated up from 0.5mg daily to a maximum of 3.0 mg daily over the first 11-week phase. Following a 4-week washout period, subjects will be crossed-over to the opposite arm for another 11 week treatment period (phase 2).
Timeline
- Start
- 2012-06
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nabilone | Other / unclassified | 3 mg | Oral |
Indications
No indication recorded.